Parsons Supporting U.S. Army Chemical and Biological Defense
On September 20, 2022, Parsons Corporation (NYSE: PSN) was awarded a 10-year IDIQ contract by the U.S. Army Combat Capabilities Development Command for chemical and biological defense support, valued at $869 million. This contract will enhance the Army's capabilities in research, development, test, and evaluation related to chemical and biological defense. Parsons aims to leverage its expertise in biosurveillance and environmental safety to contribute to national security and combat readiness.
- Awarded a 10-year IDIQ contract worth $869 million from the U.S. Army.
- Enhances Parsons' capabilities in chemical and biological defense.
- Strengthens relationships with federal clients, including various branches of the military.
- None.
CENTREVILLE, Va., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) was selected by U.S. Army Combat Capabilities Development Command, Chemical Biological Center (DEVCOM CBC) for an award on its Scientific, Technical Engineering, and Program Support Services (STEPSS) indefinite delivery, indefinite quantity (IDIQ) contract. The 10-year IDIQ, a multiple award contract with a program ceiling value of
“We stand ready to support DEVCOM CBC as they deliver on their vision of providing innovative chemical and biological defense capabilities to advance national security and global combat operations,” said Jon Moretta, president of Parsons’ engineered systems business unit. “This is an exciting win as we continue growing our biosurveillance and environmental sector capabilities. We look forward to bringing our proven talent, expertise, and mission-critical solutions to this important mission.”
STEPSS technical support tasks may include research, development, test, and evaluation; engineering, system acquisition, and engineering system development; and chemical, biological demilitarization operations. Parsons’ biosurveillance and environmental sector is a mission-oriented group of experts, technology, and products focused on keeping humans healthy and safe from known and emerging biological threats, chemical contaminants, and other hazards.
This award continues the company’s decades of experience delivering innovative chemical and biological defense solutions and services across the federal sector, including the U.S. Army Medical Research Command, Naval Health Research Center, and Naval Medical Research Center, as well as program management support to all major DoD medical organizations, including the Department of Veterans Affairs and individual branch medical services.
To learn more about Parsons’ life sciences capabilities, visit www.parsons.com/biosurveillance.
About Parsons
Parsons (NYSE: PSN) is a leading disruptive technology provider in the global defense, intelligence, and critical infrastructure markets, with capabilities across cybersecurity, missile defense, space, C5ISR, transportation, environmental remediation, and water/wastewater treatment. Our solutions around the globe help make the world safer, healthier, and more connected Please visit parsons.com, and follow us on LinkedIn and Facebook to learn how we’re making an impact.
Forward-Looking Statements
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our current expectations, beliefs and assumptions, and are not guarantees of future performance. Forward-looking statements are inherently subject to uncertainties, risks, changes in circumstances, trends, and factors that are difficult to predict, many of which are outside of our control. Accordingly, actual performance, results, and events may vary materially from those indicated in the forward-looking statements, and you should not rely on the forward-looking statements as predictions of future performance, results, or events. Numerous factors could cause actual future performance, results and events to differ materially from those indicated in the forward-looking statements, including, among others: any issue that compromises our relationships with the U.S. federal government or its agencies or other state, local, or foreign governments or agencies; any issues that damage our professional reputation; changes in governmental priorities that shift expenditures away from agencies or programs that we support; our dependence on long-term government contracts, which are subject to the government’s budgetary approval process; the size of our addressable markets and the amount of government spending on private contractors; failure by us or our employees to obtain and maintain necessary security clearances or certifications; failure to comply with numerous laws and regulations; changes in government procurement, contract or other practices or the adoption by governments of new laws, rules, regulations, and programs in a manner adverse to us; the termination or nonrenewal of our government contracts, particularly our contracts with the U.S. federal government; our ability to compete effectively in the competitive bidding process and delays, contract terminations, or cancellations caused by competitors’ protests of major contract awards received by us; our ability to generate revenue under certain of our contracts; any inability to attract, train, or retain employees with the requisite skills, experience, and security clearances; the loss of members of senior management or failure to develop new leaders; misconduct or other improper activities from our employees or subcontractors; our ability to realize the full value of our backlog and the timing of our receipt of revenue under contracts included in backlog; changes in the mix of our contracts and our ability to accurately estimate or otherwise recover expenses, time and resources for our contracts; changes in estimates used in recognizing revenue; internal system or service failures and security breaches; and inherent uncertainties and potential adverse developments in legal proceedings, including litigation, audits, reviews, and investigations, which may result in materially adverse judgments, settlements, or other unfavorable outcomes. These factors are not exhaustive and additional factors could adversely affect our business and financial performance. For a discussion of additional factors that could materially adversely affect our business and financial performance, see the factors included under the caption “Risk Factors” in our Registration Statement on Form S-1 and our other filings with the Securities and Exchange Commission. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. We assume no obligation to update any forward-looking statement made in this presentation that becomes untrue because of subsequent events, new information or otherwise, except to the extent we are required to do so in connection with our ongoing requirements under federal securities laws.
Media Contact:
Bernadette Miller
+1 980.253.9781
Bernadette.Miller@Parsons.com
Investor Relations Contact:
Dave Spille
+ 1 703.775.6191
Dave.Spille@parsons.com
FAQ
What is the value of the contract awarded to Parsons Corporation on September 20, 2022?
What will Parsons Corporation provide under the U.S. Army contract?
How long is the contract awarded to Parsons Corporation expected to last?
Which organization awarded the contract to Parsons Corporation?
What is Parsons Corporation's stock symbol?
